Targeting EGFR in bilio-pancreatic and liver carcinoma

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 16-22

  Fratto, Maria Elisabetta ^a   Santini, Daniele ^a   Vincenzi, Bruno ^a   Silvestris, Nicola ^b   Azzariti, Amalia ^b   Tommasi, Stefania ^b   Zoccoli, Alice ^a   Galluzzo, Sara ^a   Maiello, Evaristo ^c   Colucci, Giuseppe ^b   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Anti EGFR therapy; Biliary Tract Cancer; Gastric Cancer; Hepatocellular Cancer; Pancreatic Cancer; Review

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; OXALIPLATIN; SORAFENIB; VANDETANIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EPISTAXIS; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; TREATMENT RESPONSE; BILIARY TRACT TUMOR; CARCINOMA; DRUG ANTAGONISM; LIVER TUMOR; PANCREAS TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BILIARY TRACT NEOPLASMS; CARCINOMA; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955946001     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Yoon JH, GY Gwak, HS Lee, SF Bronk, NW Werneburg, GJ Gores: Enhanced epidermal growth factor receptor activation in human cholangioc arcinoma cells. J Hepatol. 41,808-814 (2004) (Pubitemid 39434311)
2. Nakazawa K, Y Dobashi, S Suzuki, H Fujii, Y Takeda, A Ooi: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 206,356-3 65 (2005) (Pubitemid 40903200)
3. Leone F, G Cavalloni, Y Pignochino, I Sarotto, R Ferraris, W Piacibello, T Venesio, L Capussotti, M Risio, M Aglietta: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 12 (6), 1680-5 (2006)
4. Ariyama H, B Qin, E Baba, R Tanaka, K Mitsugi, M Harada, S Nakano: Gefitinib, a selective EGFR tyro sine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem. 97,724-734 (2006)
5. Miyata H, T Sasaki, K Kuwahara, M Serikawa, K Cha yama: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. Int J Oncol. 28,915-921 (2006)
6. Zhang Z, AE Sirica: Simultaneous inhibition of ErbB1 and ErbB2 signaling significantly enhances the growth suppression of rat and human cholangiocarcinoma cell lines. FASEB J. 21: A71-A72 (2007)
7. Herberger B, W Berger, H Puhalla, K Schmid, S Novak, A Brandstetter, C Pirker, T Gruenberger, M Filipits: Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin p athway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol cancer Ther.8 (6),1547-56 (2008)
8. Wiedmann M, J Feisthammel, T Blüthner, A Tannapfel, T Kamenz, A Kluge, J Mössner, K Caca: Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs. 17 (7),783-95 (2006) (Pubitemid 44310175)
9. Yoshikawa D, H Ojima, A Kokubu, T Ochiya, S Kasai, S Hirohashi, T Shibata: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel moleculartargeted therapy against cholangiocarcinoma. Br J Cancer. 100 (8), 1257-66 (2009)
10. Phili p PA, MR Mahoney, C Allmer, J Thomas, HC Pitot, G Kim, RC Donehower, T Fitch, J Picus, C Erlichman: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol.. 24, 3069-3074 (2006) (Pubitemid 46638942)
11. Sprinzl MF, CC Schimanski, M Moehler, S Schadmand-Fischer, PR Galle, S Kanzler: Gemcitabine in combination with EGF-receptor antibody (cetuximab) as a treatment of cholangiocarcinoma: A case r eport. BMC Cancer.6,190 (2006)
12. Paule B, M Bralet, M Herelle, E Rage, M Ducreux, C Guettier and R Adam: Cetuximab plus gemcitabine/oxaliplatin (GEMOX) for patients with unresectable/recurrent intrahepatic cholangiocarcinoma refractory to GEMOX. J Clin Oncol. 24 (S18), 14084 (2007)
13. Paule B, MO Herelle, E Rage, M Ducreux, R Adam, C Guettier, MP Bralet: Cetuximab plu s gemcitabineoxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 72, 105-110 (2007) (Pubitemid 350249137)
14. Malka D, T Trarbach, L Fartoux, J Mendiboure, C de la Fouch ardière, F Viret, E Assenat, E Boucher, O Rosmorduc, T Greten: A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of a dvanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol. 27,15s, abstr 4520 (2009)
15. Gruenberger B, J Schueller, D Tamandl, K Kaczirek, G Schernthaner, T Gruenberger: K-ras st atus and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study. J Clin Oncol. 27,15s, abstr 4586 (2009)
16. Ramanathan RK, CP Belani, DA Singh, M. Tanaka, H J Lenz, Y Yen, HL Kindler, S Iqbal, J Longmate, DR Gandara: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EG FR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC) A California Consortium (CCC-P) Trial. J Clin Oncol. 24 (suppl 18S):Abstract 4010 (2006)
17. Tannapfel A, M Benicke, A Katalinic, D Uhlmann, F Köckerling, J Hauss, C Wittekind: Frequency of p16 (INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47 (5), 721-727 (2000)
18. Suto T, W Habano, T Sugai, N Uesugi, O Funato, S Kanno, K Saito, S Nakamura: Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 73 (3),158-163 (2000) (Pubitemid 30174210)
19. Hidaka E, A Yanagisawa, M Seki, K Takano, T Setoguchi, Y Kato: High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel i n the papilla of Vater. Cancer Res 60 (3), 522-524 (2000) (Pubitemid 30094542)
20. Rashid A, T Ueki, YT Gao, PS Houlihan, C Wallace, BS Wang, MC Shen, J Deng, AW Hsing: K-ras mutation, p53 ov erexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 8 (10), 3156-3163 (2002) (Pubitemid 35155025)
21. Simonetti RG, A Liberati, C Angiolini, L Pag liaro: Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 8:117-136 (1997) (Pubitemid 27112878)
22. Llovet JM, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF B lanc, AC de Oliveira, A Santoro, JL Raoul, A Forner, M Schwartz, C Porta, S Zeuzem, L Bolondi, TF Greten, PR Galle, JF Seitz, I Borbath, D Häussinger, T Giannaris, M Shan, M Moscovici, D Voliotis, J Bruix; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390 (2008)
23. Schiffer E, C Housset, W Cacheux, D Wendum, C D esbois-Mouthon, C Rey, F Clergue, R Poupon, V Barbu,O Rosmorduc: Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 41:307-314 (2005) (Pubitemid 40165374)
24. Ito Y, T Takeda, M Sakon, M Tsujimoto, S Higashiyama, K Noda, E Miyoshi, M Monden, N Matsuura: Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 84:1377-1383 (2001) (Pubitemid 32522107)
25. Huether A, M Hopfner, V Baradari, D Schuppan, H Scherubl: EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Bio chem Pharmacol. 70:1568-1578 (2005) (Pubitemid 41540350)
26. Buckley AF, LJ Burgart, S Kakar: Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol 37 :410-414 (2006)
27. Hamazaki K, Y Yunoki, H Tagashira, T Mimura, M Mori, K Orita: Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev 21:355-360 (1997) (Pubitemid 27335556)
28. Nakopoulou L, K Stefanaki, D Filaktopoulos, I Giannopoulou: C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: An immunohistochemical study. Histol Histo pathol 9:677-682 (1994) (Pubitemid 24327104)
29. Philip PA, MR Mahoney, C Allmer, J Thomas, HC Pitot, G Kim, RC Donehower, T Fitch, J Picus, C Erlichman: Phase II study of erlotinib (OSI-774) in pa tients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663 (2005) (Pubitemid 46190260)
30. Thomas MB, R Chadha, K Glover, X Wang, J Morris, T Brown, A Rashid, J Dancey, JL Abbruzzese: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059-1067 (2007) (Pubitemid 47312872)
31. Thomas MB, JS Morris, R Chadha, M Iwasaki, H Kaur, E Lin, A Kaseb, K Glover, M Davila, J Abbruzzese: Phase II trial of the combination of bevacizumab and erlotini b in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 20;27 (6):843-50 (2009)
32. Zhu AX, K Stuart, LS Blaszkowsky, A Muzikansky, DP Reitberg, JW Clark, PC Enzinger, P Bhargava, JA Meyerhardt, K Horgan, CS Fuchs, DP Ryan: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 1;110 (3):581-9 (2007) (Pubitemid 47106147)
33. Gruenwald V , L Wilkens, T Gebel, T Wirth, T Greten, S Kubicka, MP Manns, A Ganser, NP MalekL: A phase II openlabel study of cetuximab in unresectable hepatocellular carcinoma: final results (abstract) Proc Am Soc Clin Oncol. 25:4598a (2007)
34. Asnacios A, L Fartoux, O Romano, C Tesmoingt, S S Louafi, T Mansoubakht, P Artru, T Poynard, O Rosmorduc, M Hebbar, J Taieb: Gemcitabine plus oxaliplatin (GEMOX) co mbined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 15;112 (12):2733-9 (2008) (Pubitemid 351969218)
35. Burris HA 3rd, MJ Moore, J An dersen, MR Green, ML Rothenberg, MR Modiano, MC Cripps, RK Portenoy, AM Storniolo, P Tarassoff, R Nelson, FA Dorr, CD Stephens, DD Von Hoff: Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-13 (1997) (Pubitemid 27251144)
36. Strimpakos A, MW Saif, KN Syrigos. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 27(3):495-522 (2008)
37. Moore MJ, D Goldstein, J Hamm, A Figer, JR Hecht, S Gallinger, HJ Au, P Murawa, D Walde, RA Wolff, D Campos, R Lim, K Ding, G Clark, T Voskoglou-Nomikos, M Ptasynski, W Parulekar: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. (Pubitemid 46972777)
38. Vervenne W, J Bennouna, Y Humblet, S Gill, MJ Moore, J Van Laethem, A Shang, J Cosaert, C Verslype, E Van Cutsem: A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2008, 26:4507.
39. Xiong HQ, A Rosenberg, A LoBuglio, W Schmidt, RA Wolff, J Deutsch, M Needle, JL Abbruzzese: Cetuximab, a monoclonal antibody targ eting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 22 (13):2610-2616 (2004) (Pubitemid 41103748)
40. Philip PA, J Benedetti , C Fenoglio-Preiser, M Zalupski, H Lenz, E O'Reilly, R Wong, J Atkins, J Abruzzese, C Blanke: Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic p ancreatic adenocarcinoma (PC): SWOG S0205 study. ASCO Annual Meeting Proceedings (Post- Meeting Edition) Part I. 25: (18S June 20 suppl):LBA4509 (2007)
41. Kindler HL, T Gangadhar, T Karrison, HS Hochster, M J Moore, K Micetich, W Sun, DV Catenacci, WM Stadler, EE Vokes: Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreat ic cancer (PC) J Clin Oncol (Meeting Abstracts) 26:4502 (2008.)